Inogen stock: buy or sell?

INGN stock price: $44.72 3.30% At close on August 22nd, 2019

Updated on:
August 22nd, 2019


Inogen soared a brilliant 3.30% and closed at $44.72. On Aug/14 INGN plummed a bloodcurdling -7.06%.

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally.

Should I buy Inogen stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. At, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, Inogen stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Inogen stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At, we collected 10 ratings published for INGN stock in the last month.

Is INGN a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-8Svb LeerinkOutperformMarket Perform
2019-8-8Leerink SwannOutperformMarket Perform
2019-8-7Needham & Company LLCBuyHold
2019-7-3JPMorgan Chase & Co.NeutralUnderweight
2019-6-28Needham & Company LLCStrong-BuyBuy
2019-5-8JPMorgan Chase & Co.OverweightNeutral
2019-4-9Needham & Company LLCn/aBuy
2019-2-27Piper Jaffray Companiesn/aOverweight
2019-2-27Needham & Company LLCStrong-BuyStrong-Buy
2019-2-27JPMorgan Chase & Co.PositiveOverweight

Inogen stock analysis

Daily outlook

Inogen shares soared 3.30% to $44.72 today.

Shares of Inogen soared a brilliant 3.30% and closed at $44.72. INGN is soaring again after a 12.55% correction from its last top on August/9 at $47.49.

INGN stock chart (daily)

Weekly outlook

After sliding a chilling -6.54% in a week last week, Inogen closed this week at $44.72 and boosted a super good 6.02%.

Since early November 2018, when INGN stock price broke down the 40-weeks moving avarage line, it slid $-149.58 per share (-76.98%). Trading stocks that are below the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support. Far behind is the all-time high Inogen hit by mid September 2018 and since then the price is -84.46% below that top.

INGN stock chart (weekly)

Inogen stock price history

Inogen IPO was on February 14th, 2014 at $16.00 per share1. Since then, INGN stock grew a 179.50%, with a yearly average of 35.90%. If you had invested right after INGN's IPO a $1,000 in Inogen stock in 2014, it would worth $1,795.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Inogen stock historical price chart

INGN stock reached all-time highs on September with a price of $287.79.

Inogen stock price target is $128.00

How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we found 8 price targets for INGN stock:
INGN stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-8Svb LeerinkReiterates$78.00$47.00-39.7%
2019-7-3JPMorgan Chase & Co.Downgradesn/a$72.00-
2019-6-28Needham & Company LLCDowngrades$111.00$91.00-18%
2019-5-8JPMorgan Chase & Co.Downgrades$175.00$72.00-58.9%
2019-4-9Needham & Company LLCReiteratesn/a$191.00-
2019-2-27Piper Jaffray CompaniesLowers Target$290.00$185.00-36.2%
2019-2-27Needham & Company LLCReiterates$280.00$191.00-31.8%
2019-2-27JPMorgan Chase & Co.Lowers Targetn/a$175.00-
(in average)$186.80$128.00-31.0%
Moving in a range from $191.00 and $47.00, the price target for Inogen stock is $128.00. In average, analysts' outlook on INGN price target is negative, downgrading the target by a -31.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, Inogen reported its latest financial data, posting a dazzling gain for the Earnings per Share (EPS) ratio. Analyst expected $0.25 per share, but Inogen posted $0.44.
INGN earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Inogen annual turnover boosted an exceptional 43.57% to $358.11 million dollars from $249.44 marked in 2017. Instead, its profit margin (compared to sales) soared to 14.48%, that is $51.85 million.

INGN annual Sales and Income evolution
2013$75 M-$25 M33.7%-
2014$113 M49.17%$6.83 M6.1%-73.17%
2015$159 M41.29%$12 M7.3%69.72%
2016$203 M27.56%$21 M10.1%77.12%
2017$249 M22.98%$21 M8.4%2.35%
2018$358 M43.57%$52 M14.5%146.86%

Quarterly financial results

Inogen reported $86.53 M in sales for 2018-Q4, a -9.19% less compared to previous quarter. Reported quarter earnings marked $10.05 million with a profit margin of 11.61%. Profit margin dropped a -5.64% compared to previous quarter when profit margin was 17.24%. When comparing revenues to same quarter last year, Inogen sales marked a super good gain and skyrocketed a 35.66%. Looking back to recent quarterly results, Inogen posted 2 negative quarters in a row.
INGN quarterly Sales and Income evolution
2017-Q1$53 M-$6 M11.3%-
2017-Q2$64 M22.13%$8 M13.0%40.64%
2017-Q3$69 M7.66%$7 M10.6%-12.01%
2017-Q4$64 M-7.60%$-1 M-1.0%-108.26%
2018-Q1$79 M23.93%$11 M13.6%-1,875.25%
2018-Q2$97 M23.01%$15 M15.0%35.81%
2018-Q3$95 M-2.00%$16 M17.2%12.47%
2018-Q4$87 M-9.19%$10 M11.6%-38.87%

Inogen ownership

When you are planning to buy shares of a company, it's worth to check its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Inogen, 1.17% of all outstanding shares are owned by its staff.

Bearish positions for INGN stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Inogen:

Market cap$980.7 M$6.1 M$44.7 M$2.0 B$174.2 M
Total shares21.9 M4.0 M8.4 M31.7 M33.8 M
Float shares18.2 M3.4 M6.8 M33.9 M32.8 M
  - Institutional holdings (%)109.7%11.2%25.9%106.7%124.2%
  - Insider holdings (%)1.2%62.9%18.5%6.3%3.5%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Inogen summary

Thursday, August 22nd, 2019
Day range$42.84 - $45.05
Previous close$43.29
Session gain3.30%
Average true range$3.36
50d mov avg$59.01
100d mov avg$68.27
200d mov avg$98.97
Daily patternlb01a
Weekly pattern lb06a

Inogen performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared Inogen against Allied Healthcare Products, Electromed, Chart Industries, Invacare, Masimo, Koninklijke Philips, ResMed and XTL Biopharmaceuticals in the following table:
AHPIAllied Healthcare...-6.13%-19.47%-35.71%
GTLSChart Industries-16.62%-27.08%-13.67%
PHGKoninklijke Phili...15.51%21.42%8.52%
XTLBXTL Biopharmaceut...-28.28%-8.38%-3.85%

Inogen competitors

We selected a few stocks to conform a list of Inogen competitors to check if you are interested in investing in INGN: